IL1B and neutropenia: Case reports and series indicate that anakinra can be safely used alongside immunosuppressive agents in renal transplant recipients with IL-1 driven diseases, although one patient experienced neutropenia and decreased allograft function, with an unclear link to IL-1 blockade (100).